For those who quote AASB 8, I think ISX dealt with this superbly...

First 279 Last

Share
Profile

Follow
Senseightynine

2,026 Posts.

713

19/11/19

01:34

Post #: 41495636
Share

Originally posted by ben79: ↑

Really good response from ISX today. Much more clarity than the second round. It does appear that the ASX has a particular ideological bias against the higher risk customer base and continues to conflate ISX with the activities of its customers. ISX tried to address this in various responses, e.g. Q9 whilst remaining respectful (in tone).

I see some ongoing debate around disclosure / interpretation of materiality in various contexts. I have enjoyed the commentary on accounting standards. Fascinating. For those who quote AASB 8, I think ISX dealt with this superbly (Qst 3).

What's clear now is that there was no fraud or manipulation of revenue. Some paid downrampers here claiming integration fees are not recurring as if this precludes performance hurdles being met. For the removal of doubt, it does not. If anything, it provides a strong explanation as to why revenues in the May/ June period peaked.

I'm also satisfied with the explanations provided that revenues post 30 June were deferred rather than contracts being terminated/ lost. A number of explanations were given. It's apparent that it's not possible to fully attribute to any particular cause. Not sure how ASX can ask this question in a different way or expect a different response (than provided to Qst 19). ASX will need to form a view here either way.

Perversely, I have really enjoyed gaining a much deeper insight into the team's capabilities.

Looking forward to ASX bringing this matter to a head.

Expand

For those who quote AASB 8, I think ISX dealt with this superbly (Qst 3).

the answer only deals with asx disclosure for listing rules rather than accounting disclosure for financial reporting.

stop reading and interpreting what you want to read

ISX Price at posting: $1.07 Sentiment: None Disclosure: Not Held
1 Upvote

1 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BUX

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

There are more pages in this discussion • 157 more messages in this thread...

First 279 Last

Add SP1 (ASX) to my watchlist

For those who quote AASB 8, I think ISX dealt with this superbly...

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News